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to M E Caplin
Email
m.caplin@ucl.ac.ukAbstractIn the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged
progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuro-
endocrine tumours (NETs). We report long-term safety and additional efficacy data from the
open-label extension (OLE). Patients with metastatic grade 1/2 (Ki-67 %10%) non-
functioning NET and documented baseline tumour-progression status received lanreotide
Autogel 120 mg (nZ101) or placebo (nZ103) for 96 weeks or until death/progressive disease
(PD) in CLARINET study. Patients with stable disease (SD) at core study end (lanreotide/
placebo) or PD (placebo only) continued or switched to lanreotide in the OLE. In total,
88 patients (previously: lanreotide, nZ41; placebo, nZ47) participated: 38% had pancreatic,
39% midgut and 23% other/unknown primary tumours. Patients continuing lanreotide
reported fewer adverse events (AEs) (all and treatment-related) during OLE than core study.
Placebo-to-lanreotide switch patients reported similar AE rates in OLE and core studies,
except more diarrhoea was considered treatment-related in OLE (overall diarrhoea
unchanged). Median lanreotide PFS (core study randomisation to PD in core/OLE; nZ101)
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23 :3 192bias by assuming that patients with SD on lanreotide in the core study and not entering the
OLE (nZ13) had PD 24 weeks after last core assessment, found median PFS remaining
consistent: 30.8 months (95% CI: 30.0, 31.3). Median time to further PD after placebo-
to-lanreotide switch (nZ32) was 14.0 months (10.1; not reached). This OLE study suggests
long-term treatment with lanreotide Autogel 120 mg maintained favourable safety/
tolerability. CLARINET OLE data also provide new evidence of lanreotide anti-tumour
benefits in indolent and progressive pancreatic/intestinal NETs.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0490
q 2016 The authors
Printed in Great Britain
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(2016) 23, 191–199Introduction Patients and methodsCLARINET was a landmark 96-week study that confirmed
anti-tumour effects for the long-acting somatostatin
analogue lanreotide Autogel (depot in the USA)
120 mg. Lanreotide prolonged progression-free survival
(PFS) over placebo in patients with metastatic grade 1 or
2 (proliferation index, Ki-67, up to 10%) somatostatin-
receptor positive pancreatic, intestinal or of unknown
primary origin neuroendocrine tumours (NETs) with
prior stable disease (SD), irrespective of hepatic tumour
volume (Caplin et al. 2014). Consequently, lanreotide
Autogel/depot 120 mg is now indicated in both the US
and EU as an anti-tumour treatment for pancreatic
and intestinal NET (Ipsen 2014, 2015). Furthermore,
this novel evidence for lanreotide has prompted
re-evaluation of guidelines for first-line medical therapy
of metastatic gastroenteropancreatic NETs (NCCN 2014,
Pavel et al. 2016).
Here, we present data from the pre-planned interim
analysis of the ongoing single-arm (lanreotide Autogel
120 mg) open-label extension (OLE) to the core study.
The primary objective of the OLE study was to investigate
the long-term safety of lanreotide in patients with
pancreatic and intestinal NETs. Safety/tolerability of
lanreotide was investigated not only in patients receiving
lanreotide in both the core and OLE studies but also in
patients switching from placebo (core study) to lanreotide
(OLE). Another objective was to further examine anti-
tumour efficacy. In the core study, median PFS for placebo
was 18.0 months, but had not been reached with
lanreotide after 96 weeks. This analysis provided an
opportunity to estimate the median PFS for lanreotide
(in continued lanreotide patients) and to determine the
median time to subsequent progression in placebo-
to-lanreotide patients who had progressive disease (PD)
in the core study.Patients
Inclusion and exclusion criteria for the core study have
been published (Caplin et al. 2014) but are summarised
here to characterise the CLARINET OLE population.
The core study included adult patients with sporadic,
well- or moderately differentiated NETs that had prolifer-
ation index (Ki-67) of up to 10% and were non-function-
ing, except for gastrinomas adequately controlled with
proton pump inhibitors for R4 months. Primary tumours
were located in the pancreas, midgut or hindgut, or were of
other/unknown origin. Patients were also required to have
an unresectable locally advanced tumour or metastatic
disease (or had declined surgery), target lesion(s) classified
as at least grade 2 (Krenning scale) within the previous
6 months and a World Health Organization (WHO)
performance score of %2. Core study exclusion criteria
comprised treatment with interferon, chemoembolisation
or chemotherapy within 6 months before study entry,
radionuclide therapy at any time or a somatostatin
analogue at any time (unless received over 6 months
previously for !15 days); major surgery related to the NET
within the previous 3 months; multiple endocrine neo-
plasia; or previous cancer (except in situ cervical or uterine
carcinoma or basal-cell skin carcinoma or other cancers
treated with curative intent and disease-free for O5 years).
Patients were eligible for the OLE study if attending a
participating study centre and if they had SD (according to
response evaluation criteria in solid tumours (RECIST) 1.0)
at the end of the 96-week core study (while receiving
lanreotide or placebo) or had centrally assessed PD during
the core study while receiving placebo (Supplementary
Figure S1, see section on supplementary data given at the
end of this article). Patients’ WHO performance score had
to remain at %2 at the start of the OLE study. from Bioscientifica.com at 04/20/2021 08:06:03AM
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23 :3 193Patients could be withdrawn from the OLE study if
local assessments indicated tumour progression, or for
safety reasons. Patients could withdraw therapy at their
own request at any time.Trial design and interventions
The CLARINET OLE is a single-arm, non-randomised,
multicentre study conducted in 24 centres across ten
countries (in Europe, India and USA). Patients were
enrolled within 4 weeks of their last core study visit and
received lanreotide Autogel 120 mg by deep s.c. injection
every 28 days. The study started in February 2009 and will
continue in each country until registration for tumour
control. This pre-planned interim analysis was undertaken
at the time of last patient’s last visit in the core study
(data cut-off: March 2013).
Patients provided written informed consent. Study
protocol, amendments (amendments occurring after the
start of the study are summarised in the Supplementary
Materials and methods, see section on supplementary data
given at the end of this article) and consent form were
approved by independent ethics committees in each
country; the Declaration of Helsinki, Good Clinical Practice
guidelines and all local regulatory requirements were
adhered to. The study was registered at ClinicalTrials.gov
(NCT00842348) and EudraCT (2008-004019-36).Assessments and endpoints
The OLE study assessments (multiphase CT or dynamic
contrast-enhanced MRI scans) were scheduled for week 1
(OLE study baseline) and every 24 weeks, as well as at the
time of early withdrawal (if applicable) or at any time if PD
was suspected. Adverse events (AEs) were recorded
throughout the study on 4-weekly treatment visits.
Other safety assessments included physical examination,
assessment of vital signs and clinical laboratory tests
(all visits), and electrocardiography and ultrasonography
of the gallbladder conducted at baseline, weeks 48 and 96,
or early withdrawal visit. Scans were assessed locally for
the signs of PD according to RECIST 1.0, compared to core
study baseline scan or a subsequent scan indicating a nadir
in core or OLE studies (patients with SD in core study), or
OLE study baseline or a subsequent scan indicating a nadir
in OLE study (patients with PD in core study).
The primary objective of the OLE study was to
investigate the long-term safety of lanreotide Autogel
120 mg in patients with pancreatic and intestinal NETs.
The secondary objective was to further investigate itshttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0490
q 2016 The authors
Printed in Great Britainefficacy. This interim analysis provides an opportunity
to estimate median PFS for lanreotide in patients
originally randomised to and continuing to receive
lanreotide, both overall (main efficacy endpoint) and for
pre-specified as well as clinically relevant subgroups
(see Supplementary Materials and methods). The interim
analysis also facilitates estimation of the time to sub-
sequent PD in patients switching to open-label lanreotide
after PD while receiving placebo in the core study
(additional efficacy endpoint). Insufficient numbers
precluded evaluation of subsequent PD in subgroups.Statistical analysis
Descriptive statistics were calculated for safety data from
the safety population (all patients who received at least
one dose of lanreotide in the OLE study). Descriptive
rather than inferential statistics were performed because
this was a non-comparative OLE study, and there were
some inherent differences between patients who switched
to active drug from placebo or continued on active drug,
notably in SD/PD status at the start of this study. Safety
analyses were described for groups according to the
sequence of treatment received during the core and OLE
studies (lanreotide in both studies or placebo in core,
followed by lanreotide in OLE study).
PFS (main efficacy end point) and the time to
subsequent PD with lanreotide (additional efficacy end
point) were described using Kaplan–Meier curves with
events defined as deaths and PD (centrally assessed during
core and locally assessed during OLE study, all using RECIST
1.0); all other outcomes werecensored asper Foodand Drugs
Administration guidance (FDA 2007). Two sensitivity
analyses were performed (see the Supplementary Materials
and methods for details and for information on the
populations used for efficacy analyses). Efficacy data were
presented in months approximated to 4 weeks.
Statistical analyses were performed using SAS software
version 9.3 (SAS Institute, Inc.).Results
Patient disposition and characteristics
Of patients from the core study (nZ138) eligible for the
OLE study, 79 patients had SD at the core study end (53 on
lanreotide and 26 on placebo) and 59 had PD while
receiving placebo during the core study. In total, 52
(37.7%) patients who were eligible did not enrol, mostly
(37/52, 71.2%) because their study centres did notPublished by Bioscientifica Ltd.
Downloaded from Bioscientifica.com at 04/20/2021 08:06:03AM
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23 :3 194participate in the OLE study. Reasons for non-enrolment
were not documented for the remaining 15 patients.
Of 88 patients enrolled in the OLE study (among
whom two were ineligible, Fig. 1 and Supplementary
Figure S1), 41 continued on lanreotide and 47 patients
switched from placebo to lanreotide. At the time of the
pre-planned interim analysis, none of the 88 participants
had died.
Compared with the groups with SD on lanreotide or
placebo at the end of the core study, the group with PD
while receiving placebo contained a greater proportion
with worse WHO performance status (scores of 1 or 2) at
baseline in the OLE study and a greater proportion with a
NET originating in the pancreas (Table 1).Treatment exposure
The medians (ranges) for combined lanreotide exposure in
the core and OLE studies were 40.0 (26.0–74.3) months






























Flow of patients through the OLE study. These numbers refer to status at
the time of the OLE interim analysis. For further information, see
Supplementary Figure S1. *One patient was enrolled by investigator prior
to confirmation of centrally assessed PD (patient then withdrawn when
confirmation received). †One patient was withdrawn from the core study
for a reason other than centrally assessed PD but was then enrolled in the
OLE. AE, adverse event; LAN, lanreotide autogel 120 mg; OLE, open-label
extension; PBO, placebo; PD, progressive disease.
http://erc.endocrinology-journals.org
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Printed in Great Britainin the placebo-to-lanreotide group with SD at the end of
the core study and 13.0 months (2.0–52.0) in the placebo-
to-lanreotide group with PD during the core study.Safety/tolerability
In the continued lanreotide group, incidences of overall
and individual AEs (whether considered related to
treatment or irrespective of causality) were generally
lower for the OLE study compared with the core study
(Table 2). This difference was particularly marked for
diarrhoea and abdominal pain (Supplementary Tables S1
and S2, see section on supplementary data given at the end
of this article).
In the placebo-to-lanreotide group, the overall inci-
dence of AEs, whether treatment-related or not, was similar
across the core and OLE studies (Table 2). This pattern was
reflected across most individual AEs, except for diarrhoea.
Whereas the incidence of diarrhoea irrespective of causality
was similar between studies (most common AEs occurring
in R10% of patients shown in Supplementary Table S1),
the incidence considered to be treatment-related was
higher in the OLE study (most common treatment-related
AEs occurring in R5% of patients shown in Supplementary
Table S2). Incidences of severe and serious AEs were similar
between groups and across studies. Only one patient was
withdrawn due to a treatment-related AE (placebo-
to-lanreotide group: non-serious tumour haemorrhage
associated with serious tumour necrosis in the liver, the
patient recovered with sequelae following hospitalisation
and appropriate treatment).
The gallbladder echography was conducted on at least
two occasions during the core and OLE studies combined
in 29/41 (71%) patients in the continued lanreotide group,
and 34/47 (72%) patients in the placebo-to-lanreotide
group. Among these patients, new lithiasis and/or new
sludge were detected in four patients each in the placebo-
to-lanreotide group and six patients each in the continued
lanreotide group.
No clinically significant trends were observed in other
safety assessments.Efficacy
Median PFS was not reached for lanreotide in the 96-week
core study (Caplin et al. 2014). With data from the OLE
study at the time of the pre-planned interim analysis
appended to data from the core study, median PFS in
patients receiving lanreotide Autogel 120 mg was esti-
mated to be 32.8 months (95% CI: 30.9, 68.0) (Fig. 2).Published by Bioscientifica Ltd.
Downloaded from Bioscientifica.com at 04/20/2021 08:06:03AM
via Universita Cattolica Sacro Cuore
Table 1 Demographic and disease characteristics for participants in the OLE study according to the treatment sequence they




No PD during core study
(nZ15)
PD during core study
(nZ32)
Men, n (%) 18 (43.9) 6 (40.0) 19 (59.4)
Age, mean (S.D.) in yearsa 64.9 (10.9) 59.5 (12.0) 62.1 (9.3)
Time since diagnosis, mean (S.D.) in months 36.5 (58.8) 34.7 (45.0) 45.2 (47.5)
WHO performance status score, n (%)a
0 – normal activity 35 (85.4) 13 (86.7) 21 (65.6)
1 – restricted activity 6 (14.6) 2 (13.3) 10 (31.3)
2 – in bed %50% of the time 0 0 1 (3.1)
Prior NET treatment, n (%) 5 (12.2) 4 (26.7) 5 (15.6)
NET origin, n (%)
Pancreas 11 (26.8) 5 (33.3) 17 (53.1)
Midgut 17 (41.5) 7 (46.7) 10 (31.3)
Hindgut 5 (12.2) 1 (6.7) 1 (3.1)
Other/unknown 8 (19.5) 2 (13.3) 4 (12.5)
Tumour progression at, n (%)
Core study baseline 0 1 (6.7) 3 (9.4)
OLE study baseline 1 (2.4)b 0 32 (100)
Tumour grade, n (%)
G1 (Ki-67 0–2%) 30 (73.2) 12 (80.0) 20 (62.5)
G2 (Ki-67 3–10%)c 11 (26.8) 3 (20.0) 12 (37.5)
Hepatic tumour load, n (%)
0% 9 (22.0) 2 (13.3) 10 (31.3)
O0–10% 19 (46.3) 10 (66.7) 9 (28.1)
O10–25% 1 (2.4) 3 (20.0) 4 (12.5)
O25–50% 10 (24.4) 0 5 (15.6)
O50% 2 (4.9) 0 4 (12.5)
Data are from assessments at core study baseline or aOLE study baseline and are for patients receiving lanreotide Autogel 120 mg in both CLARINET core and
OLE studies (LAN–LAN group), and patients receiving placebo in the core study and crossing over to lanreotide in the OLE study (PBO–LAN group).
bPatient enrolled by the investigator before communication of the results of the central assessment (PD) in the core study; patient withdrawn from the
OLE study upon receipt of the assessment results.
cKi-67 thresholds as per WHO 2010 classification with values O2 to %10% assigned to tumour grade 2.
LAN, lanreotide Autogel 120 mg; NET, neuroendocrine tumour; OLE, open-label extension; PBO, placebo; PD, progressive disease; SD, standard deviation;
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23 :3 195In total, 23 patients from this continued lanreotide group
are ongoing in the OLE study without PD (Fig. 1).
Supportive analysis (based on the per-protocol
population) provided the same estimate of median PFS
for lanreotide as the main (intention-to-treat (ITT))
analysis: 32.9 months (95% CI: 30.9, 68.0). In the a priori
sensitivity analysis, data from 15 patients who were
withdrawn from the core study due to investigator
assessment of PD (despite central assessment of SD) were
added as events. Compared with the main analysis,
median (95% CI) PFS for lanreotide in the sensitivity
analysis was similar (31.3 months (24.0, 49.0)). In the post
hoc sensitivity analysis, data from 25 patients (13 receiving
lanreotide) with SD at the end of the core study but who
did not enter the OLE study were added to the analysis,
and all were assumed to have had PD at the first OLE study
assessment. Median PFS for lanreotide in this sensitivity
analysis was consistent with the main analysis: 30.8
months (95% CI: 30.0, 31.3).http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0490
q 2016 The authors
Printed in Great BritainFor patients who had PD (nZ32) while receiving
placebo in the core study and continued into the OLE
study (receiving open-label lanreotide), 17 had subsequent
PD during the OLE; a median time from first PD in the core
study with placebo to subsequent PD in the OLE study
with lanreotide was 14.0 months (95% CI: 10.1, not
reached) (Fig. 3). Nine patients are continuing to receive
lanreotide treatment in the OLE study without subsequent
PD (reasons for discontinuation are shown in Fig. 1 and
Supplementary Figure S1). For patients without PD on
placebo after completing the full 96 weeks of the core
study (nZ15), three patients experienced PD with lanreo-
tide Autogel 120 mg in the OLE study (one of three who
withdrew for PD did not have PD; one patient was ongoing
with PD at time of interim analysis). Nine patients were
continuing lanreotide treatment without PD at the time of
interim analysis.
For continued lanreotide patients, PFS results in the
core plus OLE studies across subgroups based on tumourPublished by Bioscientifica Ltd.
Downloaded from Bioscientifica.com at 04/20/2021 08:06:03AM
via Universita Cattolica Sacro Cuore
Table 2 Incidence of AEs in the core and OLE studies among participants of the OLE study according to the treatment sequence
(safety population)
LAN–LAN group (nZ41) PBO–LAN group (nZ47)
Core study OLE study
Both studies
(pooled) Core study OLE study
Any patients with an AE 38 (92.7) 27 (65.9) 39 (95.1) 44 (93.6) 38 (80.9)
Treatment-related 22 (53.7) 11 (26.8) 25 (61.0) 13 (27.7) 19 (40.4)
Severe 11 (26.8) 10 (24.4) 16 (39.0) 11 (23.4) 11 (23.4)
Moderate 17 (41.5) 11 (26.8) 16 (39.0) 26 (55.3) 20 (42.6)
Mild 9 (22.0) 6 (14.6) 6 (14.6) 7 (14.9) 7 (14.9)
Missing 1 (2.4) 0 1 (2.4) 0 0
Any patients with serious AEs 10 (24.4) 9 (22.0) 15 (36.6) 10 (21.3) 10 (21.3)
Treatment-related 3 (7.3) 1 (2.4)a 3 (7.3) 1 (2.1) 1 (2.1)a
Withdrawals due to AEs NAb 2 (4.9)c 2 (4.9) NA 1 (2.1)c
Treatment-related NAb 0 0 NA 1 (2.1)
Most common individual AEsd
Diarrhoea 14 (34.1) 4 (9.8) 15 (36.6) 15 (31.9) 15 (31.9)
Abdominal pain 12 (29.3) 3 (7.3) 13 (31.7) 7 (14.9) 6 (12.8)
Constipation 8 (19.5) 2 (4.9) 9 (22.0) 5 (10.6) 1 (2.1)
Nausea 7 (17.1) 2 (4.9) 8 (19.5) 5 (10.6) 4 (8.5)
Dizziness 7 (17.1) 2 (4.9) 7 (17.1) 1 (2.1) 2 (4.3)
Cholelithiasis 6 (14.6) 4 (9.8) 9 (22.0) 5 (10.6) 2 (4.3)
Headache 6 (14.6) 2 (4.9) 8 (19.5) 6 (12.8) 4 (8.5)
Vomiting 6 (14.6) 2 (4.9) 8 (19.5) 4 (8.5) 5 (10.6)
Hypertension 6 (14.6) 2 (4.9) 7 (17.1) 3 (6.4) 5 (10.6)
Data are number (%) of patients with an AE while receiving lanreotide Autogel 120 mg or placebo. AEs were defined according to the Medical Dictionary
for Regulatory Activities (MedDRA) version 16.0. LAN–LAN group, patients receiving lanreotide Autogel in core study as well as the OLE study; PBO–LAN,
patients receiving placebo in the core study before crossing over to lanreotide in the OLE study. AE, adverse event; OLE, open-label extension.
aOne patient experienced cholelithiasis (LAN–LAN group) and one experienced tumour necrosis (PBO–LAN group).
bNA, not applicable (no patients withdrawn from the core study were entered into the OLE study).
cAt the time of the pre-planned interim analysis of the OLE study, two withdrawals had been reported due to AEs in the LAN–LAN group: ileus was not
considered related to treatment, and tumour pain was subsequently confirmed not to be the reason for withdrawal (withdrawal due to protocol violation);
one patient in the PBO–LAN group withdrew due to tumour necrosis (also reported as a serious AE) and tumour haemorrhage, which were reported to be
treatment related.
dBased on MedDRA preferred terms, full list of AEs occurring in R10% patients are listed in Supplementary Table S1, and treatment-related AEs occurring in
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therapy status at core study baseline and region were gene-
rally consistent with the main analysis (Supplementary
Table S3, see section on supplementary data given at the
end of this article). Numbers of placebo-to-lanreotide
patients were insufficient to assess time to subsequent PD
across subgroups after switching to lanreotide.Discussion
The CLARINET OLE study further investigates the safety
and efficacy of lanreotide in patients with metastatic
pancreatic and intestinal NETs. The long-term safety and
tolerability profile of lanreotide Autogel 120 mg was
favourable during a median treatment duration of 40
months (continued lanreotide group; range: 26–74 months).
Among patients who received lanreotide in the core and
OLE studies, the pattern of most AEs suggests amelioration
with increasing duration of treatment exposure, particularly
for diarrhoea (whether treatment-related or not). In thehttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0490
q 2016 The authors
Printed in Great Britaingroup switching from placebo in the core study to
lanreotide in the OLE study, the pattern of AEs between
studies shows generally comparable rates, including
treatment-related AEs except for diarrhoea, which was
higher in the OLE study. The latter finding was not
unexpected, as diarrhoea is a common transient side effect
after the initiation of somatostatin analogue therapy.
The safety and tolerability profile of lanreotide is well-
evidenced from its use as a treatment for symptoms of
carcinoid syndrome in clinical studies (Ruszniewski et al.
2004, Bajetta et al. 2006) and many years of clinical
practice in numerous countries worldwide (Khan et al.
2011, Palazzo et al. 2013). This experience is consistent
with the favourable safety data observed in the CLARINET
core study and this OLE study. Indeed, the safety/toler-
ability profile shown here further supports the use of this
agent early in the treatment pathway for NETs and over
the long term. The incidence and nature of treatment-
related AEs among patients switching from placebo to
lanreotide in the OLE either align broadly with or comparePublished by Bioscientifica Ltd.
Downloaded from Bioscientifica.com at 04/20/2021 08:06:03AM
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median (core study), 18.0 months
(95% CI: 12.1, 24.0)
Lanreotide autogel 120 mg
45 events/101 patients (core: 32 events/101 patients;
OLE: 13 events/40 patients)
Median (core plus OLE studies), 32.8 months (95% CI: 30.9, 68.0)
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Time from randomization in core study (months)
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Figure 2
PFS on lanreotide in the core and OLE studies, at the time of the pre-
planned interim analysis, and on placebo in the core study (ITT population).
Data in months are approximated based on 4 weeks per month. Median PFS
was not reached for patients receiving lanreotide Autogel 120 mg during
the 24-month core study (vs 18.0 months for patients receiving placebo).
Core study data are for all patients randomly allocated to double-blind
treatment (lanreotide or placebo); the OLE study data are only for patients
originally randomly allocated to lanreotide in the core study who then
continued into the OLE study. *Previously reported as 60 events (Caplin
et al. 2014) because one patient was erroneously reported as having
centrally assessed SD at the time of core study database lock; this has been
revised in the OLE study analysis. ITT, intention-to-treat population;
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2004, Bajetta et al. 2006). Furthermore, a lower incidence
of AEs, in particular diarrhoea and abdominal pain,
occurred in the group continuing lanreotide treatment
in the OLE study.
Overall, the efficacy data are consistent with con-
tinued anti-tumour effects. Key findings include the 32.8-
month estimate for median PFS in patients originally
randomised to lanreotide in the core study, which
contrasts with the 18.0-month median PFS for placebo
reported previously (Caplin et al. 2014). The OLE study
data provided an estimated 14.0-month time to pro-
gression with lanreotide in patients with PD on placebo in
the core study; this information is clinically important,
with the caveat that it is based on data available for only
32 of 59 potentially eligible patients.
The CLARINET core study is, to date, the most
comprehensive and robust study of the anti-tumour effects
of a somatostatin analogue in patients with metastatic
NETs. Lanreotide significantly prolonged PFS in a large
population with advanced grade 1 or 2 (Ki-67 up to 10%)
pancreatic and intestinal NETs and indolent disease (96%
SD according to RECIST), irrespective of hepatic tumourhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0490
q 2016 The authors
Printed in Great Britainload; median PFS for lanreotide was not reached (Caplin
et al. 2014). The OLE efficacy data extend the duration of
lanreotide use among the CLARINET patient population
and have allowed the median PFS to be estimated. These
observations accord well with limited data on anti-tumour
treatment with lanreotide available before CLARINET from
observational studies. A single-centre UK study reported
a 5-year PFS rate of 59% with lanreotide for 76 patients
with mostly low-grade midgut NETs (Khan et al. 2011).
A multicentre study from France of lanreotide treatment
found median PFS of 29 months in a cohort of 68 patients
with metastatic NETs (foregut 28%/midgut 59%; 54% liver
burden %25%) (Palazzo et al. 2013).
The CLARINET OLE study additionally provides
evidence that lanreotide has an anti-tumour effect in
patients with PD. The 14.0-month estimated PFS in the
population of patients with progressive pancreatic and
intestinal NETs is similar to the 12.9 months estimated in a
phase II uncontrolled study involving 30 patients with
progressive NETs (lung 13%/gastrointestinal 47%/pancrea-
tic 27%) receiving lanreotide for %92 weeks (Martin-
Richard et al. 2013). Time-to-progression in two patients
with midgut NETs treated with octreotide after progressingPublished by Bioscientifica Ltd.
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Median, 14.0 months (95% CI: 10.1, NC)
6 12 18 24 30
Time from centrally assessed PD in core study (months)
Numbers of patients at risk of death or PD
32 26 16 11 8 6 6 3 1 0
36 42 48 54
Figure 3
Time to death or subsequent PD, at the time of the pre-planned interim
analysis, in patients with PD on placebo in the core study who switched to
lanreotide in the OLE study (subset of the ITT population). Data in months
are approximated based on 4 weeks per month. Data are from patients
originally randomised to placebo in the core study, who have experienced
PD in the core study and then switched to lanreotide Autogel 120 mg in the
OLE study. NC, not calculable. ITT, intention-to-treat population;
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23 :3 198on placebo in the PROMID study was 14.0 and 16.0 months
(Rinke 2012) (31% of the OLE PD subgroup had midgut
NETs). Although a direct comparison is not feasible, the
CLARINET data are broadly consistent with PFS reported in
phase III studies of other targeted agents in patients with
progressive pancreatic NETs (11.0 months for everolimus in
the RADIANT-3 study (Yao et al. 2011), 11.4 months for
sunitinib (Raymond et al. 2012)), although only 53% of the
PD subgroup in the CLARINET OLE study had pancreatic
NETs. Together then, the core and OLE data advance our
understanding of the anti-tumour effects of lanreotide,
supporting its positive benefit/risk profile as one of the
recommended first-line therapy options for metastatic
pancreatic and intestinal NETs either for prevention or
for inhibition of tumour growth (NCCN 2014).
Undoubtedly, extensions of large randomised con-
trolled trials such as CLARINET are important; however,
the OLE study is not without limitations. Firstly, not all
eligible core study patients continued to be followed into
the OLE study, principally owing to non-participation of
some core study centres; nonetheless, a degree of selection
bias may have occurred. However, as noted, this issue was
addressed in a post hoc sensitivity analysis that included all
patients with SD in the core study who did not continue
into the OLE study and designated them as having PD at
the first OLE assessment. Reassuringly, median PFS from
this sensitivity analysis accorded well with the mainhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0490
q 2016 The authors
Printed in Great Britainanalysis. Secondly, the OLE study was not specifically
designed to measure efficacy, and in contrast to the core
study, it was open-label, lacked a control group and based
PFS estimates on locally rather than centrally assessed PD.
Nevertheless, the estimate of median PFS for lanreotide
was based on the ITT population from the randomised
controlled core study and, in large part, on events
confirmed centrally during the core study.
In summary, the CLARINET OLE study demonstrated
that the long-term treatment with lanreotide Autogel
120 mg was well-tolerated, with no indication of new safety
concerns. Notwithstanding study limitations, the CLAR-
INET OLE data suggest that lanreotide Autogel 120 mg has
anti-tumour effects in patients with PD. Additionally, the
CLARINET core and OLE studies together provide evidence
for long-term PFS benefits of lanreotide Autogel 120 mg in
patients with indolent pancreatic and intestinal NETs.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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